Department of Pharmacology, Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH.
Int J Cancer. 2014 Mar 1;134(5):1013-23. doi: 10.1002/ijc.28226. Epub 2013 May 28.
The evolutionally conserved DNA damage response (DDR) and cell cycle checkpoints preserve genome integrity. Central to these genome surveillance pathways is a protein kinase, Chk1. DNA damage induces activation of Chk1, which then transduces the checkpoint signal and facilitates cell cycle arrest and DNA damage repair. Significant progress has been made recently toward our understanding of Chk1 regulation and its implications in cancer etiology and therapy. Specifically, a model that involves both spatiotemporal and conformational changes of proteins has been proposed for Chk1 activation. Further, emerging evidence suggests that Chk1 does not appear to be a tumor suppressor; instead, it promotes tumor growth and may contribute to anticancer therapy resistance. Recent data from our laboratory suggest that activating, but not inhibiting, Chk1 in the absence of chemotherapy might represent an innovative approach to suppress tumor growth. These findings suggest unique regulation of Chk1 in cell biology and cancer etiology, pointing to novel strategies for targeting Chk1 in cancer therapy.
进化保守的 DNA 损伤反应(DDR)和细胞周期检查点可保持基因组完整性。这些基因组监测途径的核心是一种蛋白激酶,Chk1。DNA 损伤可诱导 Chk1 的激活,随后将检查点信号转导,并促进细胞周期停滞和 DNA 损伤修复。最近,人们在理解 Chk1 调节及其在癌症发病机制和治疗中的意义方面取得了重大进展。具体而言,提出了一种涉及蛋白质时空和构象变化的模型来激活 Chk1。此外,新出现的证据表明,Chk1 似乎不是肿瘤抑制因子;相反,它促进肿瘤生长,并可能导致抗癌治疗耐药。我们实验室的最新数据表明,在没有化疗的情况下激活 Chk1(而非抑制 Chk1)可能代表抑制肿瘤生长的一种创新方法。这些发现表明 Chk1 在细胞生物学和癌症发病机制中的独特调节作用,为癌症治疗中靶向 Chk1 提供了新的策略。